2023 World Conference on Lung Cancer (Posters)-EP13.07. Efficacy and Safety of Antiangiogenic Therapy plus Immunotherapy as Later-line Treatment for Small Cell Lung Cancer

EP13.07. Efficacy and Safety of Antiangiogenic Therapy plus Immunotherapy as Later-line Treatment for Small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the efficacy and safety of combining anti-angiogenic therapy with immune checkpoint inhibitors (ICIs) as second or later-line treatment for small cell lung cancer (SCLC). The medical records of SCLC patients who received either the combination therapy or anti-angiogenic monotherapy were retrospectively analyzed. The primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse reactions (AEs). <br /><br />A total of 52 patients were included in the study, with 33 in the combination therapy group and 19 in the monotherapy group. The baseline characteristics of the two groups were comparable. The combination therapy group had a longer PFS compared to the monotherapy group (3.6 vs. 2.7 months). Cox regression analyses supported the combination therapy as a significant protective factor against disease progression. Female gender and no prior immunotherapy also showed a decreasing trend in the risk of disease progression. The combination group also had a better disease control rate (DCR) compared to the monotherapy group. There was no significant difference in the incidence of adverse reactions between the two groups. <br /><br />In conclusion, the combination of ICIs and antiangiogenic therapy showed superiority in disease control and delayed progression compared to anti-angiogenic monotherapy in second or later-line treatment for SCLC. These results offer a potential therapy option and suggest the need for further verification in prospective clinical trials.

Asset Subtitle

Yutao Liu

Meta Tag

Speaker Yutao Liu

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

efficacy

safety

anti-angiogenic therapy

immune checkpoint inhibitors

small cell lung cancer

retrospective analysis

progression-free survival

disease control rate

adverse reactions

therapy option